Skip to content

MBX Biosciences

US · MBX #2567 by market cap Listed 2024
49.55 -3.86 -7.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 52.92 -0.92%
After-hours 49.55 0.00%
70.7029.0049.552026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MBX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +29.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 8.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -27.8% Better than 14%
Return on invested capital -31.3% Better than 10%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -25.3% Better than 23%
6-month return 55.6% Better than 96%
12-month return (ex latest month) 79.1% Better than 92%
Distance below 52-week high 31.8% Better than 40%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 24.6x Better than 99%
Debt to assets 0.2% Better than 98%
Interest coverage -68.9x Better than 6%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 98.4% Better than 83%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.42%
1M -7.38%
3M -25.32%
6M +57.65%
YTD +57.10%
1Y +83.31%

Key statistics

Price & volume

Prev close
53.41
Open
53.48
Day range
49.36 - 54.43
Avg price
50.76
Volume
581.89K
Turnover
29.54M
Amplitude
9.49%
52-week range
26.14 - 72.64

Valuation

P/E
-20.82
P/E (TTM)
-16.35
P/B
5.20
EPS
-2.38
Net profit
-118.18M
Net assets
472.93M

Share structure

Market cap
2.46B
Float cap
1.55B
Shares out
49.66M
Float shares
31.23M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-09-13
52-week range 50% of range
26.14 72.64

31.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-10.91M net over the window

Short interest

Shares short
4.29M
As of
2026-10-30

Frequently asked questions

What is the current stock price of MBX Biosciences (MBX)?

MBX Biosciences last traded at 49.55. This page shows a periodic quote snapshot. Check the displayed quote time.

What is MBX Biosciences's market cap?

About 2.46B.

What is the P/E ratio of MBX Biosciences?

The trailing twelve-month P/E is -16.35. The Valuation tab shows it against the stock's own five-year range.

Does MBX Biosciences pay a dividend?

MBX Biosciences does not currently pay a regular dividend.

Is MBX Biosciences a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 98.33, which implies 98.4% upside from the current price. This is not investment advice.

What is MBX Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates MBX Biosciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

MBX Biosciences discussion 0 comments

Add a comment